Skip to main content
Markets · Live
DJIA50,687.07▼ -1.21%S&P 5007,553.68▼ -0.74%Nasdaq26,853.98▼ -0.89%Nvidia—▼ TSMC—▼ Alphabet—▼ Bitcoin—▼ DJIA50,687.07▼ -1.21%S&P 5007,553.68▼ -0.74%Nasdaq26,853.98▼ -0.89%Nvidia—▼ TSMC—▼ Alphabet—▼ Bitcoin—▼
New York--:--
Chicago--:--
Denver--:--
Los Angeles--:--
Honolulu--:--
Anchorage--:--
Tokyo--:--
Berlin--:--
London--:--
UTC--:--

Breaking

BLOOMBERG MARKETS — Fed Looks Set to Pause After September Rate Hike · Oct 25, 10:07 AM ET
Inc.

A Nobel Prize Winner’s Startup Raised $350 Million. Now It Can’t Fund Its Cancer Programs

The Berkeley gene-editing company will wind down its lymphoma and myeloma studies and explore a potential sale.

Rachel Suleymanov
By Rachel Suleymanov· Inc.· Published

Rights: fair use excerpt

No AI assistance disclosed

A Nobel Prize Winner’s Startup Raised $350 Million. Now It Can’t Fund Its Cancer Programs
Reporting by Rachel SuleymanovSource: Inc.Updated October 25, 2026
PHOTO: INC.

---

Rachel Suleymanov · Inc.

Source & Credit

Reporting and photography credited as noted above. Originally published by Inc..

Members only

Checking your membership…